A suspicious disc or red OCT sector is a starting point. Confirm quality and correspondence, then assess progression and an individual pressure target.
Terminology and draft status
Terminology review is not complete. No new WHO UMD entry verification is claimed for this copy; pending entries and limits are recorded in terminology.md.
01Suspected glaucoma: what do we examine first?
When glaucoma is suspected, assess six areas: history, intraocular pressure (IOP), drainage angle, optic disc, retinal nerve fibre layer (RNFL) and visual field. The disc is the visible optic nerve head; the visual field tests visual function. 1 3
Then ask: Is damage already present? Is glaucoma suspected? Or is only the risk increased? One pressure reading, a large cup or a red OCT mark cannot answer this alone. 1 3
Ask about family glaucoma, previous pressures, operations, myopia and eye injuries. Review all medicines, especially corticosteroids as drops, tablets or other preparations. 2
Check previous results and treatment. Look for pseudoexfoliation material and pigment dispersion at the slit lamp. Symptoms and systemic disease help determine urgency and later treatment. 2
Ocular hypertension (OHT) means raised pressure without demonstrated glaucomatous damage. Pressure, disc appearance, OCT or visual fields may raise suspicion of glaucoma. 1
In preperimetric glaucoma, convincing structural damage is present without a typical visual field defect yet. Before using this diagnosis, check for measurement errors and other optic nerve diseases. 1
Compare OCT with the visual field. OCT may show early damage more clearly; visual fields may be more useful in advanced disease. There is no fixed sequence for every eye. 1 15
Histological estimates of 20–50% cell loss are not OCT cut-offs. They cannot tell us the GCL thickness at which an individual must develop a visual field defect. 1 15
02Optic disc: what do we see and what does it mean?
Assess the disc stereoscopically at the slit lamp. Start with size, shape and orientation. Then check rim width and colour, notches, RNFL defects, haemorrhages and vessels. 1
Inspect the surrounding tissue too. Photograph the baseline for later comparison. Always judge a large cup against the size of the disc. 1
The ISNT rule describes usual rim width: inferior > superior > nasal > temporal. It is most helpful in medium-sized discs. 1
Large, small and tilted discs often differ. A violation calls for further assessment but does not diagnose glaucoma. A small disc can be damaged despite having little cupping. 1
The cup-to-disc ratio (CDR) compares cup size with disc size; here we use the vertical measurement. A CDR of 0.7 can be normal in a large disc. A small disc may be damaged even with a CDR of 0.3. 1 2
With an inter-eye difference of about 0.2, first compare disc sizes. Then check the rim, OCT and visual field. Do not diagnose from a fixed CDR cut-off alone. 1 2
Measure vertical disc diameter with a narrow slit. Record the lens and its correction factor. EGS 6 gives about 1.9 mm as an average, not a boundary between health and disease. 1 12 13
The older EGS 4 table gives factors of 1.36–1.59 for different 90 D lenses. Example: with an appropriate factor of 1.36, 1.2 mm × 1.36 is about 1.63 mm. Check your lens factor; it does not apply to every 90 D lens. 1 12 13
Notching is a focal indentation of the rim. Bayoneting is a sharp bend of a vessel at the cup edge. Exposed vessels along the cup may also suggest rim loss. 1
Visible laminar pores and cup depth add descriptive detail but cannot determine stage alone. Marked pallor or unexpectedly poor acuity should prompt assessment for other optic nerve diseases, especially when disc and field findings do not fit. 1
Myopia can tilt, rotate or stretch the disc and nerve fibre pattern. The tilt direction alone cannot establish a neurological diagnosis. 1 8
A grey crescent is a grey area inside the disc margin. It can make the visible rim appear smaller than it is. Locate the true disc edge and distinguish this from atrophy outside the disc. 1 8
The alpha zone has irregular pigmentation beside the disc. The beta zone is closer to the disc edge, with visible sclera or larger choroidal vessels. 1
Beta atrophy also occurs in myopia and in older healthy eyes. Document its size and changes. A larger area alone does not prove glaucoma progression. 1
Look for optic disc haemorrhages (Drance haemorrhages) and photograph a new finding. Compare OCT and visual fields with earlier tests, then reassess pressure and risk factors. 1 9
A haemorrhage increases concern about disease or progression but may have other causes. A rule based on half a disc diameter cannot prove its cause. 1 9
Reykjavik 2005: A cross-sectional study assessed photos of 1012 right eyes in people aged 50 or older. 22% had a grey crescent. An association with glaucoma was not demonstrated: OR 1.05; 95% CI 0.49–2.26. OR means odds ratio, a statistical comparison of the presence of disease. 8 9
In practice: A grey crescent can make the rim look too small. The study proves neither that it is congenital nor that it remains harmless throughout life. 8 9
Budenz/OHTS 2017: This was a prospective observational analysis within OHTS. Participants were followed over time. Annual stereo photos covered 3236 eyes of 1618 people. The median follow-up was 13 years: the middle of the follow-up distribution. Haemorrhages were detected in 179 eyes. 8 9
Result: Over the studied period, 25.6% of eyes with haemorrhage and 12.9% without developed POAG. The time-dependent HR adjusted for baseline risks was 2.6 (95% CI 1.7–4.0). Nevertheless, 78% of haemorrhage eyes did not reach a POAG endpoint during a median 49 months after haemorrhage. 8 9
Limits: Annual photos can miss short-lived haemorrhages. Eyes with baseline haemorrhage were excluded. Haemorrhage was the only risk factor occurring during follow-up that was included in the model. 8 9
Random assignment to medication reduced haemorrhage rate: HR 0.70 (95% CI 0.52–0.95). This differs from asking whether every new haemorrhage should trigger a particular treatment. That strategy was not tested by randomisation. Document and monitor a new haemorrhage more closely; do not infer current progression or a specific treatment from it alone. 8 9
The original disc values average1.7mm (1.5–2.2), microdisc<1.5 and macrodisc>2.2 are descriptive conventions, not universal disease cutoffs. CDR0.1–0.5, >0.7 in5% and inter-eye difference0.2 also depend on disc size and population. A yellow-orange rim, pallor, vertical disc/horizontal cup shape and visible laminar pores add context; none defines glaucoma alone. 1 18
| Parameter | Descriptive range | Interpretation |
|---|---|---|
| Disc diameter | Original1.7mm (1.5–2.2);micro<1.5/macro>2.2 | Population/lens dependent;size not disease |
| CDR | Original0.1–0.5;>0.7 quoted in5% | Assess rim/disc size, not a universal threshold |
| Inter-eye CDR difference | Original<0.2 versus>0.2 | Compare disc sizes and corresponding damage |
| Rim colour | Yellow-orange versus pallor | Pallor prompts differential assessment;not synonymous with neurological disease |
03Reading OCT: images before colours
OCT images retinal layers and measures their thickness. It does not count living ganglion cells. Circle scans around the disc measure RNFL; radial disc scans assess the rim. Macular scans show inner retinal layers. 1
A 3.4 mm circle is only a protocol example. Scan shape and analysis depend on the device. Spectral-domain and swept-source are different OCT techniques; this does not establish universal superiority of a brand. 1
GCL means ganglion cell layer. GCIPL includes GCL and the inner plexiform layer. Depending on the software, GCC may also include RNFL. 1
Check which layers and area the device report actually measures. Do not directly compare absolute values across devices. Use the same system for follow-up where possible and record software changes. 1
Open the B-scans, the cross-sectional images, first. Are they sharp and centred? Are there motion errors or cloudy media? Do the drawn layer boundaries follow the actual anatomy? This automatic boundary detection is called segmentation. 1 14
Only then interpret the colours. A Spectralis Q value around 15 is a minimum in certain protocols, not a guarantee of a correct scan. Segmentation may be wrong even with a good signal. 1 14
Check alignment with the line between disc and fovea. Follow-up scans must return to the same location; this is called registration. The colour compares the measurement with a reference database. 1
Myopia, torsion, unusual disc size or wrong segmentation can mark healthy areas red ('red disease'). A green overall value may hide a local defect. Check individual areas and original images. 1
With central field defects or a difficult disc, also inspect the macula. Glaucoma damage often follows arcuate nerve fibre bundles and the horizontal raphe, the line between upper and lower bundles. 1
Vertically bounded patterns may fit disease at or behind the chiasm. A 'snail-shaped' pattern alone is not a diagnosis. Macular disease and myopia can also alter GCIPL. 1
No isolated GCL thickness below40–45µm, a snail-shaped pattern or a single brand establishes glaucoma. Structure and field can disagree at any stage. Interpret a thick/abnormal macula and high myopia with particular care; neither isolated layer analysis nor a device quality score replaces clinical correlation. 1 18
04Follow-up OCT: real change or measurement error?
With a large change over a few weeks, open both original scans side by side. Were the same location and region measured? Check signal, segmentation, media and software. 1
Then decide whether the change is real or a measurement error. The teaching example '31 µm in 20 days' is retained. Without the original data, we cannot attribute it to vascular pulsation. 1
Healthy RNFL also thins with age. A healthy study group's average does not tell us how much loss is safe for an individual. 1 7
A trend line shows how quickly measurements change. A statistically significant decline must also fit image quality, defect location, stage and visual field. One test or non-comparable devices cannot establish a reliable trend. 1 7
The 'floor' is the range where OCT can barely measure further thinning. Residual tissue and the analysis method set this limit. There is no universal 40 µm point at which OCT should be stopped. 1 6
Give visual fields more weight in advanced glaucoma. Also check whether the macula or local OCT areas can still show change. GCC and RNFL do not necessarily reach their floors together. 1 6
Leung 2012: An observational study assessed 100 healthy people once. A random subset of 35 also underwent repeated tests over a mean 30 months. 7
Result: Global RNFL thinned by an average 0.52 µm/year, reported as −0.52 µm/year (95% CI −0.86 to −0.17). Individual sectors changed at different rates. 7
Limits: Only 35 people in follow-up, limited duration and a particular device context. The abstract and results report were read, not the full text; complete individual longitudinal data were unavailable. 7
In practice: This explains the commonly cited figure of about 0.5 µm/year. Do not subtract that value from every patient's trajectory. 7
Bowd 2017: This study assessed OCT measurement limits. In 41 eyes with moderate-to-advanced damage, five measurements over five weeks estimated variability. A second, independent group had 87 advanced eyes and only two measurements over a mean 1.8 years. 6
Estimated floors: MRW 105 ±15.9 µm; GCIPL 38 ±3.4 µm; cpRNFL 38 ±4.2 µm. The respective measured areas still above floor were 19%, 36% and 14%. 6
Important: These percentages describe areas within the study group. They do not describe how many diseased eyes the test detects; they are not diagnostic sensitivities. 6
Limits: With only two follow-up measurements, the rate of decline is imprecise. It is difficult to check whether change follows a straight line. The study used Spectralis and its own SALSA layer analysis in selected stages. 6
In practice: Macular GCIPL may still have measurable areas in advanced glaucoma. The study did not compare treatment decisions or demonstrate better preservation of vision. 6
05Measuring and interpreting eye pressure
Goldmann applanation tonometry (GAT) is the clinical reference method. It measures the force needed to flatten a defined corneal area. The Imbert–Fick principle explains this in a simplified model; a real cornea does not fully fit that model. 1
Check calibration, fluorescein amount and alignment of the semicircles. Keep the patient relaxed. Fluorescein rings ('mires') that are too broad or narrow can alter the reading. 1
Hold the lids open without pressing on the globe. Ask the patient to breathe normally and avoid straining. Posture and time of day also affect pressure; a fixed 6 mmHg addition is inappropriate. 1
Repeat an unexpected reading under good conditions. High pressure with pain or sudden visual loss requires urgent assessment. 1
CCT means central corneal thickness. Thickness, curvature and mechanical properties affect pressure measurement. Interpret readings especially carefully after refractive surgery or with corneal oedema. 1 5
Measure CCT and record it alongside the measured IOP. A blanket formula cannot give a reliably 'true' pressure. A value within the statistical normal range does not exclude glaucoma. 1 5
Other tonometers can help in children, difficult positioning or unusual corneas. Record device, model and measurement conditions during follow-up. 1
Two devices may track high and low values similarly yet differ substantially in the same eye. Good correlation is not the same as good agreement. Examine the differences and their variability too. 1
A diurnal profile or supervised home measurement can reveal fluctuations missed at one visit. Triggerfish is a contact lens sensor. It records shape changes at the corneoscleral region for up to 24 hours and may help identify a useful time for tonometry. 1 10
Its readings are not directly mmHg values. Implantable sensors are also being studied. Assess added benefit, cost and procedural risk; they do not simply replace the baseline examination. 1 10
The water drinking test measures the pressure response to a defined amount of water under controlled conditions. Studies use, for example, 800 mL, 1000 mL or 10 mL/kg. It cannot diagnose alone and is not a self-test. 11
The earlier 'four litres' statement is not a verified instruction. Assess medical suitability and fluid restrictions first. Simply waiting 1–2 hours cannot replace assessment of a concerning finding. 11
Brandt 2012: The authors recalculated the OHTS prediction model using five CCT correction formulae. The question was prediction of later POAG, not tonometer accuracy. 5
Participants: 1433 of 1636 people had all required data. Median follow-up was seven years. Correcting IOP did not improve prediction: c-statistics 0.754–0.775 versus 0.774 in the original model (Table 3). 5
The c-statistic describes how well the model separates later disease from non-disease. The result supports considering measured IOP and CCT separately. It does not mean that corneal mechanical properties are unimportant. 5
Limits: Only complete datasets from a selected OHT group were analysed. CCT was measured after random treatment assignment. The compared linear models were mathematically similar. 5
In practice: This was not a randomised device comparison or a test of every postoperative cornea. It guarantees neither a personal risk estimate nor a general formula for 'true' IOP. 5
Excess fluorescein can overestimate GAT and too little can underestimate it, but tear-film and technique matter. Avoid lid/globe pressure, breath-holding, Valsalva and a tight collar during measurement; a fixed6mmHg correction is not justified. The original word Lomegan is unresolved and is not treated as a verified device or medicine effect. 1 18
| Method | Principle | Use and limitation |
|---|---|---|
| Perkins | Portable applanation | Useful supine/children when feasible;technique and cornea matter |
| Tono-Pen | Small-area applanation | Selected difficult corneas;not automatically accurate through oedema/scars/contact lenses |
| iCare | Rebound | Often no topical anaesthetic;model/training and cornea matter for children/home use |
| ORA | Air-puff response/hysteresis | Biomechanical information, not guaranteed protection from error in keratoconus |
| Triggerfish | Contact-lens shape sensor | Up to24h patterns;not direct mmHg or a calibrated nocturnal pressure peak |
06Gonioscopy: examining the angle
Gonioscopy asks: Is the angle open, narrow or closed? Is there a secondary cause of raised pressure? A normal central anterior chamber, the disc or IOP cannot answer this. 1 3
Use dim light and document all four quadrants. Excessive light or lens pressure can artificially open a narrow angle. 1 3
Identify Schwalbe's line, trabecular meshwork, scleral spur and ciliary body band. Record angle width, pigment, abnormal vessels and signs of trauma or pigment dispersion. PAS are peripheral anterior synechiae: adhesions between iris and angle. 1
During indentation, apply gentle pressure with a suitable gonioscopy lens. Appositional closure may open; an adhesion remains. Examine the angle without indentation too. 1
Van Herick estimates peripheral anterior chamber depth at the slit lamp. AS-OCT images the anterior segment. UBM means ultrasound biomicroscopy and also shows structures behind the iris. 1
These methods complement gonioscopy. They do not assess pigment, synechiae and secondary causes in the same way. A narrow-angle AS-OCT image alone should not determine treatment. 1
07Comparing OCT and fields, recording the baseline
Perform standard automated perimetry as a baseline test. Check strategy, refractive correction, fixation, false-positive responses, fatigue and media opacity. Repeat a new or implausible defect; the AAO benchmark also recommends repeat testing for newly detected glaucomatous damage in a suspect. 1 17
Then compare locations: superior RNFL damage fits an inferior field defect. Exact agreement is not required. Measurement variability and disease stage may explain differences. 1 17
With central symptoms, macular GCIPL change or suspected damage near fixation, test the central field more densely. 24-2c and 10-2 do not sample it identically. 1
PSD measures local irregularity in the field. GHT is the Glaucoma Hemifield Test, comparing upper and lower regions. Neither value can decide alone. Detailed interpretation and progression analysis belong in the visual field chapter. 1
Record at baseline: history and risks, acuity and pupils, anterior segment and fundus, IOP with device and time, CCT, gonioscopy, disc photo or imaging, original OCT images and reliable visual fields. AAO benchmarks list these core areas and also corneal hysteresis, a measure of the cornea's response to loading. 1 17
If tests conflict, check quality first. Consider retinal or neurological causes where appropriate. Record the unresolved question rather than presenting an uncertain diagnosis as definite. 1 17
08Planning follow-up and reviewing target pressure
Assess progression using good, comparable tests. Event analysis asks: Has something changed from baseline? Trend analysis asks: How quickly is it changing across visits? 1
Check whether the change repeats and fits defect location and visual function. Age and remaining life expectancy help assess future visual risk. Do not delay an urgent clinical decision just to obtain a perfect test series. 1
Target pressure is the range we aim to reach with treatment. It is not a diagnostic boundary. Set it according to stage, previous pressure, rate of worsening, life expectancy and treatment burden. 1 17
For POAG requiring treatment, the AAO benchmark starts with at least a 25% reduction from untreated baseline. Arithmetic example: a 25% reduction from 24 mmHg gives 18 mmHg. This is not a ready-made target for everyone. More severe or rapidly worsening damage may need a lower range. 1 17
Below 12 mmHg or single-digit targets may be justified in selected progressing eyes. They do not apply automatically to every advanced or normal-tension glaucoma. 1 17
NICE NG81 uses 24 mmHg for certain OHT referral and treatment decisions. Disc or field damage may also justify referral regardless of that value. 3
For OHT, NICE also considers the risk of visual impairment over the person's lifetime. Thus 24 mmHg is neither a universal disease boundary nor a target. This UK recommendation is not a DOG/BVA rule. 3
The DOG/BVA S2e guideline 045-015 of 3 March 2024 addresses risk factors and early detection. A screening interval for a healthy person at risk is not automatically suitable for established or progressing glaucoma. 2 3
Distinguish recommendation strength from supporting evidence. A strong recommendation may rest on limited data and expert consensus. NICE lists CCT measurement during assessment; this does not mean applying an IOP correction formula. 2 3
At follow-up, ask about new symptoms, systemic disease, drop side effects and the last administration time. Check acuity, anterior segment, IOP, disc, RNFL/macula and visual fields. Repeat CCT after events that alter corneal thickness, such as refractive surgery. 17
Repeat gonioscopy with suspected closure, a shallower anterior chamber, angle abnormalities or unexplained IOP change. With progression despite reaching target, AAO also advises assessing missed pressure fluctuations and actual drop use before revising target and treatment. 17
High lifetime risk or advanced damage may require shorter intervals. Acute findings and postoperative care follow their own urgency. 17
OHTS 2002: 1636 people aged 40–80 were randomly assigned to drops or observation. No glaucomatous damage was present at baseline. IOP was 24–32 mmHg in one eye and 21–32 mmHg in the other. 4
Result at 60 months: Estimated POAG incidence was 4.4% with drops and 9.5% with observation. HR 0.40; 95% CI 0.27–0.59. The absolute difference is 5.1 percentage points, giving an NNT of about 20 over five years for this study group. 4
Meaning: About 20 comparable people would need five years of treatment to prevent one additional POAG onset. The endpoint was disease onset, not blindness. A person with a different baseline risk has a different absolute benefit. 4
Masking: Participants and treating doctors knew the group. Reading centres and the endpoint committee did not. Intention-to-treat analysis kept participants in their original assigned groups. 4
Missing data: Inactive participants were 10.9% with medication and 10.2% with observation. Assignment deviations affected 4.9% and 5.1%. Similar attrition rates do not rule out missing-data bias. 4
The 9.5% comes from a Kaplan–Meier estimate of risk at 60 months. This method accounts for different observation times. It is not the crude proportion of all events across the whole observation period: 89/819 =10.9%. 4
In practice: Not every person with OHT has 9.5% risk. Pressure of 24 mmHg or more alone does not require treatment. 4
At target, no progression; controlled for ≤6 months; Mild to moderate: 3–6 months; Severe: 3–4 months. 17
At target, no progression; controlled for >6 months; Mild to moderate: 6–12 months; Severe: 3–6 months. 17
At target, but progressing; Mild to moderate: 1–3 months; Severe: 1–2 months. 17
Not at target and progressing; Mild to moderate: 1–2 months; Severe: 1–2 months. 17
Not at target, no progression; Mild to moderate: 1–6 months; Severe: 1–3 months. 17
09Using findings to decide the next step
With a red OCT sector, first ask: Is the original image correct? Does the defect fit the disc or visual field? If not, check segmentation and reference data before diagnosing glaucoma. 1
With confirmed worsening despite 'normal' pressure, reassess measurement conditions, pressure over time, risks and target. The goal is to preserve vision and quality of life; a stable device number alone is insufficient. 1
OCT angiography, iris vessel density, implantable sensors and AI are being studied as additional tools. A good research result does not yet show that patients keep useful vision longer. 1
AUC describes how well a test separates groups in a study. It proves neither better treatment nor less vision loss. Association or more frequent measurements also cannot establish this. The separate research briefings are retained; each study still needs appraisal. 1
| Topic | Finding | Next step | Evidence boundary | Warning |
|---|---|---|---|---|
| Disc | ISNT, CDR, lens factor1.36x when appropriate | Correlate structure/function | No universal0.7 or lens factor | Pallor or discordant field |
| RNFL | Disc–fovea alignment/quality | Comparable scans and fields | 0.5µm/year ageing and40µm floor not individual stop rules | Artefacts and residual measurable areas |
| GCL/GCIPL | Horizontal pattern, macular context | Check layers, segmentation and differential | <40–45µm/snail shape not diagnostic | Myopia, macular and neurological disease |
| GAT | Imbert–Fick approximation/mires | Repeat under sound conditions, record CCT | No universal6mmHg correction | Lid pressure/straining;Lomegan unresolved |
| Progression | Disc haemorrhage/peripapillary change | Photo, quality, IOP, fields and risk review | 31µm/20days does not prove pulsation | Recurrent haemorrhage or confirmed deterioration |
What are the main learning points?
A suspicious disc or red OCT sector is a starting point. Confirm quality and correspondence, then assess progression and an individual pressure target.
When is assessment urgent?
High pressure with pain, a red eye, sudden visual loss or a neurological warning sign requires urgent assessment.
References and access status
- 1EGS. Terminology and Guidelines for Glaucoma, 6th edition (2025). DOI: 10.1136/bjophthalmol-2025-egsguidelines.
Historical005 source record (3–6October2026), not new full-source access: Full guideline inspected: clinical diagnosis, tonometry, disc, OCT, gonioscopy, visual field and individual target pressure. Published 8 September 2025.
- 2DOG/BVA. S2e Bewertung von Risikofaktoren für das Auftreten des Offenwinkelglaukoms, AWMF 045-015 (3March2024).
Historical005 source record (3–6October2026), not new full-source access: Full text inspected. Risk factors and early detection; not a comprehensive treatment guideline. Distinguish recommendation strength from evidence level.
- 3NICE NG81. Glaucoma: diagnosis and management (updated 26.01.2022).
Historical005 source record (3–6October2026), not new full-source access: Current recommendations inspected, sections 1.1.4–1.1.5, 1.2.1 and 1.4.4. 24 mmHg is a context-dependent threshold, not a universal diagnostic or target pressure.
- 4Kass et al. Ocular Hypertension Treatment Study (2002). PMID: 12049574.
Historical005 source record (3–6October2026), not new full-source access: Original full text, including methods and Table 3, inspected on 3 October 2026. Open treatment with masked endpoint assessment; distinguish Kaplan–Meier risk from crude event proportions.
- 5Brandt et al. Adjusting IOP for CCT does not improve OHTS prediction models (2012). PMID: 21705084.
Historical005 source record (3–6October2026), not new full-source access: Original full text on the trial website inspected on 3 October 2026, methods and Table 3. Model reanalysis, not a randomised comparison of correction strategies; CCT remains clinically informative.
- 6Bowd et al. Estimating OCT structural measurement floors (2017). PMID: 27914978.
Historical005 source record (3–6October2026), not new full-source access: Original full text inspected 04.10.2026: 41 eyes had five measurements over five weeks; an independent 87-eye group had only two measurements over a mean 1.8 years. Spectralis/SALSA; floors and area proportions are not universal thresholds or diagnostic sensitivities.
- 7Leung et al. Retinal nerve fibre layer imaging: impact of normal ageing (2012). PMID: 22264886.
Historical005 source record (3–6October2026), not new full-source access: Primary abstract accessible: 100 healthy participants cross-sectionally, 35 longitudinally, mean 30 months. Full text unavailable; do not derive an individual ageing correction.
- 8Jonsson et al. Optic disc grey crescent in the Reykjavik Eye Study (2005). PMID: 15615743; PMCID: PMC1772477.
Historical005 source record (3–6October2026), not new full-source access: Full text inspected; population-based cross-sectional study, 1012 right eyes. Morphological variant, not a progression study.
- 9Budenz et al. Detection and prognostic significance of optic disc haemorrhages during 13 years of OHTS (2017). PMID: 27832941.
Historical005 source record (3–6October2026), not new full-source access: Prospective OHTS cohort analysis; original full text inspected 05.10.2026: annual photographs, median 13 years and a time-dependent association. Baseline haemorrhage was excluded, transient events were probably underestimated and haemorrhage was the only intercurrent factor modelled; not a randomised post-haemorrhage treatment strategy.
- 10FDA. SENSIMED Triggerfish De Novo review, DEN140017.
Historical005 source record (3–6October2026), not new full-source access: Original regulatory assessment inspected. Pressure-related dimensional patterns; no direct IOP output in mmHg.
- 11Influence of body weight on IOP in the water drinking test (2018). PMID: 30067521.
Historical005 source record (3–6October2026), not new full-source access: Original protocol: 800 mL, 1000 mL or 10 mL/kg. Does not support a four-litre rule or self-testing; not a universal routine substitute.
- 12EGS. Terminology and Guidelines, 4th edition; Figure 1.11, disc-size assessment.
Historical005 source record (3–6October2026), not new full-source access: Historical full text inspected, Figure 1.11: 90-D lens correction factors 1.36–1.59 depending on model. Historical clinical calibration, not a universal current device specification.
- 13Volk. Slit lamp lenses: manufacturer specifications, 90D.
Historical005 source record (3–6October2026), not new full-source access: Original technical document visually inspected. Image magnification and laser spot factor are different quantities; not a diagnostic outcome study.
- 14Liu et al. Artifacts in Spectralis OCT RNFL imaging (2015). PMID: 25498118; PMCID: PMC4423408.
Historical005 source record (3–6October2026), not new full-source access: Retrospective artefact analysis. Quality score 15 belongs to the studied Spectralis context; raw-image review remains necessary.
- 15A Critical Discussion of the Structure–Function Relationship in Glaucoma (2019). PMID: 31688445.
Historical005 source record (3–6October2026), not new full-source access: Methodological discussion; abstract inspected, not an original randomised diagnostic study. Supports distinguishing histological cell counts, OCT layers and function.
- 16AAO. Primary Open-Angle Glaucoma Preferred Practice Pattern 2025; journal version online 09.02.2026.
Historical005 source record (3–6October2026), not new full-source access: Current PPP journal article identified; its full text remains unread. The official AAO Summary Benchmarks of December 2025 were read separately (reference 17); recommendations from them are attributed to the benchmark.
- 17AAO. Glaucoma Summary Benchmarks for Preferred Practice Pattern Guidelines (December 2025), pp. 1–9.
Historical005 source record (3–6October2026), not new full-source access: Supplied original PDF read in full on 6 October 2026: diagnosis pp. 3/6, follow-up and consensus interval table p. 5, angle closure pp. 8–9. Official summary, not the full PPP. The 2020 in the stable AAO URL is not the edition date of the linked 2025 benchmark.
- 18Immutable original export; clinical glaucoma evaluation; speaker attribution unchecked
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
Original lecture link
For patients
Glaucoma assessment combines several examinations. A pressure number or scan colour alone cannot tell whether your optic nerve is damaged or stable.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
High pressure with pain, a red eye, sudden visual loss or a neurological warning sign requires urgent assessment.
High pressure with pain, a red eye, sudden visual loss or a neurological warning sign requires urgent assessment.